HCPCS code J0570 – Buprenorphine implant

Key takeaways

HCPCS Code J0570 covers one 74.2 mg buprenorphine implant rod (Probuphine), billed per rod alongside CPT 11981, 11982, or 11983.

CMS discontinued J0570 effective January 1, 2025 and reactivated it on October 1, 2025, so check the date of service first.

CMS records ReacX Pharmaceuticals, Inc. as the manufacturer of record, not Braeburn, so confirm availability before planning buy-and-bill.

Probuphine has no active FDA-listed NDC and both historical NDCs were deleted, so ask the payer in writing what to report.

Medicare Part B reimburses J0570 at ASP+6%, and rates update quarterly against the current CMS ASP payment file.

Prescribers must hold active Probuphine REMS certification before administering and billing J0570, and missing REMS documentation is a leading denial cause.

Practice management software like Pabau supports structured J-code documentation and NDC reporting for buy-and-bill drug billing workflows.

HCPCS Code J0570: Description, category, and clinical use

HCPCS Code J0570 describes buprenorphine implant, 74.2 mg. It belongs to the J-code category within HCPCS Level II, which covers drugs administered by routes other than oral.

One unit of J0570 represents one 74.2 mg buprenorphine implant rod. A full Probuphine treatment consists of four rods inserted subdermally in the upper arm. A complete initial insertion therefore requires four units of J0570, billed alongside the appropriate CPT procedure code.

CMS established J0570 effective January 1, 2017. The FDA had approved Probuphine in May 2016, and the CMS HCPCS Level II code set was updated to carry it. Ownership of the product has moved since then. Titan Pharmaceuticals and Braeburn ended their Probuphine license agreement, and Titan divested the ProNeura implant assets in 2023.

The CMS Q2 2025 HCPCS application summary names ReacX Pharmaceuticals, Inc. as having acquired Probuphine from Titan. ReacX is therefore the manufacturer of record for coding purposes. Any payer policy, drug file entry, or internal fee schedule still naming Braeburn is out of date.

Contact ReacX Pharmaceuticals or an authorized specialty distributor to confirm whether the product can currently be acquired. Buy-and-bill only applies once the practice can purchase and stock the implant.

J0570 code status: Deleted in 2025, reactivated in October 2025

J0570’s history is broken in the middle. CMS discontinued the code effective January 1, 2025, then reactivated it in the October 2025 HCPCS Level II update. For nine months of 2025 the code was not valid for new claims. The timeline below tracks the code against what happened to the product itself.

That history matters in two places. Claims with a date of service between January 1 and September 30, 2025 may reject on code validity alone, whatever the documentation shows. Payer drug files and clearinghouse edits updated during the deletion window may still carry J0570 as invalid.

The reactivation was also tied to a stated relaunch intent in the CMS filings, not to confirmed commercial availability. Before you bill, check the date of service against the active windows. Then ask the payer how it wants services from the deletion window reported, and get that answer in writing.

Medicare reimbursement and fee schedule for J0570

Medicare Part B reimburses J0570 under the Average Sales Price (ASP) methodology at ASP plus 6%. The 6% add-on is intended to cover acquisition and handling costs for buy-and-bill drugs. Because ASP is recalculated from manufacturer-reported data each quarter, the payment rate for J0570 changes four times per year.

Verify the current rate using the CMS Physician Fee Schedule lookup or the quarterly ASP payment file before submitting claims. A static fee schedule drifts out of date within a few months, which leaves the practice either under-collecting or overbilling.

Reconcile each remittance against the quarter’s published ASP rate rather than an expected amount carried over from last year. The remittance shows the rate that was applied, the patient coinsurance, and any secondary payer coordination.

Medicaid coverage

Medicaid coverage for J0570 varies significantly by state. Most state Medicaid programs cover buprenorphine implants as part of their opioid use disorder treatment benefits. Coverage criteria, reimbursement rates, and prior authorization requirements still differ between them.

Some states reimburse at or near the Medicaid drug rebate-adjusted rate. Others have carved OUD drugs into managed behavioral health plans with separate formularies. Contact your state Medicaid agency or MAC for the applicable fee schedule before billing.

NDC crosswalk for J0570

Many payers, including Medicare Part B and most state Medicaid programs, require the National Drug Code (NDC) on the claim line alongside J0570. Probuphine has no active NDC in FDA data as of the last verification for this guide. Neither openFDA nor FDA DailyMed returns a current listing for the product.

Two NDCs existed historically, and both are now dead. The Braeburn listing, 58284-0100, was deleted in June 2019. The Titan listing, 52440-0100, was deleted in August 2021. They are recorded here for reconciling old claims or an archived drug file, and neither belongs on a claim submitted today.

Verify current NDC status directly with ReacX Pharmaceuticals or against FDA DailyMed before billing. If no active NDC is published for the product you hold, get written direction from the payer on what to report in the NDC field. Do not substitute a deleted NDC or one belonging to another buprenorphine product, which is a common shortcut and an avoidable compliance problem.

When an active NDC is available, report it on a CMS-1500 or 837P claim in the 11-digit format in the shaded portion of Box 24. The qualifier for J0570 is UN (unit), and the quantity equals the number of implant rods billed.

Leaving the NDC field blank is a common denial trigger for buy-and-bill drugs. Payers use the NDC to confirm that the billed code matches the drug the practice purchased. With no published NDC for Probuphine, that field is where a J0570 claim is most likely to stop. Get payer direction before the insertion date, not after the rejection.

How to bill J0570 step by step

J0570 billing follows a buy-and-bill workflow. The provider acquires Probuphine from the manufacturer of record or an authorized specialty distributor. The practice then administers the implant and bills the payer for both the drug and the procedure. Sourcing is the step to settle first, because current availability of the product is not confirmed.

1. Check the code status for your date of service. J0570 was deleted effective January 1, 2025 and reactivated on October 1, 2025. Services delivered in that window need payer direction before you submit or resubmit a claim.
2. Confirm the product is available. Contact ReacX Pharmaceuticals or an authorized specialty distributor to establish whether Probuphine can be acquired and on what terms. Buy-and-bill assumptions from older payer policies do not settle this.
3. Verify REMS certification. Before administering Probuphine, confirm the prescribing clinician holds active Probuphine REMS program certification. Claims submitted without a certified prescriber are denied and may trigger a compliance audit.
4. Confirm payer coverage and prior authorization. Contact the payer to verify J0570 coverage and determine whether PA is required. Document the authorization number in the patient record before the procedure date, and confirm active Part B or Medicaid enrollment at the same time.
5. Acquire the drug and document acquisition cost. Obtain Probuphine from the authorized distributor and retain the invoice, including the NDC or product identifier printed on it. The ASP+6% payment is tied to the acquisition price, so keep the documentation in case of payer audit.
6. Administer the implant and document in the clinical record. Record the procedure date, anatomical site (upper arm, subdermal), number of rods inserted, lot numbers, and NDC. Complete documentation supports medical necessity and claim integrity.
7. Select companion CPT codes. Bill the appropriate insertion or removal CPT code alongside J0570 (see the CPT companion codes section below).
8. Complete the claim with NDC, ICD-10, and units. Report the NDC the payer has directed you to use, plus the applicable OUD ICD-10 diagnosis code. Add the number of J0570 units, one per rod, and the companion CPT code. Use claims management software to validate the claim before submission.
9. Submit and monitor the remittance. Reconcile the payment against the expected ASP+6% rate. A claim carrying every required field should adjudicate within standard Medicare processing times.

Companion CPT codes for buprenorphine implant procedures

J0570 covers only the drug cost. A separate CPT code must always be billed to report the surgical procedure of inserting or removing the implant. Omitting the procedure code — or billing it without J0570 — results in an incomplete claim.

ICD-10 diagnosis codes supporting J0570 claims

Every J0570 claim requires a covered OUD diagnosis code to establish medical necessity. The primary covered diagnoses are in the F11 series (opioid-related disorders) from ICD-10-CM. MAC local coverage determinations and published payer policies commonly accept the codes below. Individual payer policies still differ, so verify the covered diagnosis list before claim submission.

The clinical record must substantiate the chosen diagnosis with documented substance use history, severity, and treatment rationale. Maintenance treatment claims most often carry F11.20, so check that the note supports dependence rather than abuse before the claim goes out.

Prior authorization requirements for J0570

Prior authorization requirements for J0570 vary across payer types. Medicare Part B does not currently require PA for J0570 as a standard national policy. Individual MAC jurisdictions and Medicare Advantage plans frequently impose their own requirements. Most commercial payers and state Medicaid programs require PA before the procedure date.

The submission typically needs an OUD diagnosis, treatment history, and proof of prescriber REMS certification. It also needs a clinical justification for the implant over sublingual buprenorphine formulations. Confirming eligibility and PA status before the procedure is scheduled avoids the most common denial pattern for this code.

Probuphine REMS program and prescriber certification

Prescribers cannot administer or bill J0570 without completing the Probuphine REMS program, a Risk Evaluation and Mitigation Strategy mandated by the FDA. The program requires training on patient selection criteria and on the insertion and removal procedure before a clinician can order or administer Probuphine.

A claim from a prescriber without active certification will deny, and the denial reason code rarely names REMS as the cause. Billing staff can spend days chasing the wrong problem before anyone checks the certificate.

Keep a record of REMS certification for each prescriber who bills J0570, and include it in the documentation package for any payer audit. The FDA oversees the program. Current requirements are published in the FDA REMS database and on the Probuphine REMS program website, now administered under ReacX Pharmaceuticals. A lapse in enrollment can produce a denial and compliance exposure even where the prescriber was certified previously.

Documentation requirements for J0570 claims

J0570 is a high-cost, physician-administered drug billed under a controlled substance REMS program. That combination draws post-payment review more often than a routine office procedure. The documentation below should be retrievable for any claim, ideally from the patient record rather than a separate folder.

• Covered OUD diagnosis. The F11 series code billed on the claim, supported by documented substance use history, severity, and treatment rationale.
• Clinical justification for the implant. Why a subdermal implant was chosen over a sublingual or buccal formulation for this patient.
• Active REMS certification. Evidence that the administering prescriber held certification on the date of service, not only at credentialing.
• Drug acquisition invoice. The purchase record showing the product, the identifier printed on it, and the acquisition cost behind the ASP+6% payment.
• Procedure note. Date of service, anatomical site, number of rods inserted or removed, lot numbers, and the clinician who performed the procedure.
• Prior authorization record. The authorization number and its valid date range, where the payer requires one.
• Payer direction on NDC reporting. Written confirmation of what to report while no active NDC is published for the product.

Capturing these at the point of care is far cheaper than reconstructing them during an audit. A structured template forces rod count, lot numbers, and the REMS check at documentation time. That removes the omissions that most often surface months later.

Related buprenorphine HCPCS codes: J0571, J0572, J0573

J0570 is one of four buprenorphine-related HCPCS codes. Coders often confuse J0570 with the sublingual formulation codes J0571, J0572, and J0573. The drug names are similar and the products treat the same indication, which makes the wrong-code denial a frequent one. The distinction turns on the dosage form: J0570 is the subdermal implant only, and the other three cover oral transmucosal formulations at different dose strengths.

The clinical setting also differs. J0570 is reported for a physician-administered subdermal procedure in an office or outpatient setting. J0571 through J0573 typically apply to dispensed oral medications in opioid treatment programs (OTPs) or similar settings. Always confirm the correct code based on the product administered, not the ICD-10 diagnosis code alone.

Verify current HCPCS Level II definitions against the CMS list of CPT/HCPCS codes each year. Our reference library of HCPCS codes carries the same unit and documentation detail for the rest of the J-code range.

Common billing errors and compliance tips for HCPCS Code J0570

J0570 denials tend to cluster around a small number of preventable errors. A single four-rod Probuphine claim carries meaningful revenue exposure, so each one is worth catching before submission rather than after. Below are the most common billing mistakes and how to avoid them.

• Wrong code for the formulation. Billing J0571, J0572, or J0573 for the subdermal implant — or the reverse — is the single most frequent error. Verify the HCPCS code matches the specific product administered, not just the drug name.
• Incorrect unit count. One unit of J0570 equals one 74.2 mg implant rod. A complete initial insertion of four rods requires four units on the claim line. Billing one unit for the whole set of four rods produces a significant underpayment.
• Missing or invalid NDC. Payers match the NDC on the claim to their drug file. Probuphine has no active FDA-listed NDC, and both historical codes were deleted years ago. Submitting a deleted NDC, or one borrowed from another buprenorphine product, is an automatic denial and a compliance exposure.
• Dates of service inside the 2025 deletion window. J0570 was not valid between January 1 and September 30, 2025. Claims dated in that period can reject on code validity alone, so ask the payer how it wants those services reported.
• Payer policy that still names Braeburn. Older coverage policies and internal fee schedules name Braeburn as the manufacturer. CMS records ReacX Pharmaceuticals, Inc. as the current rights-holder, so update those references before they drive a sourcing or authorization error.
• Missing companion CPT code. J0570 cannot stand alone. The implant insertion or removal CPT code (11981, 11982, or 11983) must be on the same claim. A J0570 line without a companion procedure code is incomplete and will deny.
• Non-REMS-certified prescriber. Claims submitted under a billing provider who is not enrolled in the Probuphine REMS program are denied. REMS certification must be active on the date of service, not just at the time of initial credentialing.
• Stale ASP rate in the fee schedule. Using a prior-quarter ASP rate when calculating expected reimbursement creates reconciliation errors. Update the expected payment rate each quarter from the CMS ASP payment file.
• No prior authorization on file. For commercial and Medicaid payers that require PA, submitting without an authorization number or with an expired one is a straightforward denial. Confirm PA status before every insertion date.

Compliance for J0570 also means keeping the evidence retrievable for a retrospective audit. Four records carry that weight. They are the OUD diagnosis, the REMS certification, the drug acquisition invoice, and the procedure note. Payers that cover high-cost implant drugs typically subject them to post-payment review.

Where one of those four records cannot be produced, the practice can owe a refund even though the service itself was appropriate. Check that your charge-capture template for J0570 records every required field at the point of service.

How practice management software simplifies J0570 billing

In many practices, J0570 runs across three disconnected systems. The clinical note lives in the chart. The REMS certificate and the acquisition invoice live in a shared drive. The claim is keyed separately from both. The three records only come together when a payer asks for all of them at once.

Practice management software like Pabau keeps the drug claim and its evidence in one record. Procedure templates capture rod count, lot numbers, and anatomical site as structured fields, so a four-rod insertion cannot be documented as one unit. Prescriber credentials, including REMS certification and its renewal date, sit against the clinician record and are visible before the appointment is booked.

On the billing side, claims are validated against the required fields before submission rather than after a rejection. Remittance data then posts back against the expected ASP rate. Both steps leave an audit trail. With a nine-month deletion window and unresolved NDC status behind this code, payer questions do come up. That trail lets a biller answer one in minutes instead of days.

Struggling with J-code billing documentation?

Pabau helps OUD treatment practices structure their buy-and-bill workflows, capture NDC data at the point of care, and submit cleaner claims. See how it works for your practice.

Book a demo

Conclusion

HCPCS Code J0570 sits where controlled substance prescribing, buy-and-bill drug billing, and REMS compliance meet. Its denials are rarely as simple as a missing modifier, and two checks now come before all the familiar ones. Confirm the date of service falls inside an active code window, and confirm with ReacX Pharmaceuticals that the product can be sourced.

After that, four checks prevent most denials. They are unit count, NDC direction from the payer, REMS certification, and prior authorization confirmed before the procedure date. None of them is difficult on its own. They fail because each one lives in a different system, and nobody checks all four before the claim is keyed.

Practices that administer Probuphine regularly do better with billing workflows that enforce these checks at the point of care rather than at claim submission. To see how Pabau handles J-code documentation, NDC capture, and claim validation, book a demo with the team.

Continue your research

Billing the sublingual formulation instead? HCPCS Code J0571 covers oral buprenorphine, billed per 1 mg rather than per implant rod.

Need the combination product code? HCPCS Code J0572 covers buprenorphine/naloxone up to 3 mg buprenorphine, with its own unit and coverage rules.

Want to decode the rejection you already have? Denial codes in medical billing explains what each remittance code means and how to work it.

Cleaning up your buy-and-bill documentation? What is medical billing walks through the end-to-end billing cycle from charge capture to payment posting.

Frequently asked questions